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Objective To assess the absolute risk of fetal loss associated with
hereditary deficiencies of antithrombin (AT), protein C (PC) and
protein S (PS), and the contribution of additional thrombophilic
defects to this risk.
Design A retrospective family cohort study.
Setting A tertiary referral teaching hospital.
Population Women from families with hereditary deficiencies of
AT, PC and PS, and their non-deficient relatives.
Methods We assessed the absolute risk of fetal loss, comparing
deficient women with non-deficient female relatives.
Main outcome measures Early, late and total fetal loss rates; odds
ratios of fetal loss.
Results We evaluated 289 women, who had 860 pregnancies. The
total fetal loss rates were 23% (AT deficient), 26% (PC deficient),
11% (type-I PS deficient) and 15% (type-III PS deficient),
compared with 11, 18, 12 and 13% in non-deficient women,
respectively. Odds ratios were 2.3 (95% CI 0.9–6.1), 2.1 (95% CI
0.9–4.7), 0.7 (95% CI 0.2–1.8) and 1.1 (95% CI 0.6–2.0), none of
which reached statistical significance. Differences were mainly the
result of higher late fetal loss rates in women deficient in AT (OR
11.3, 95% CI 3.0–42.0) and PC (OR 4.7, 95% CI 1.3–17.4). The
concomitance of factor-V Leiden and prothrombin G20210A was
observed in 19% of women, and did not increase the risk of fetal
loss.
Conclusions Although absolute risks of fetal loss were high, odds
ratios of total fetal loss were not statistically significant in
deficient versus non-deficient women. However the higher
absolute risks appeared to reflect higher late fetal loss rates as
opposed to early fetal loss rates. An additional effect of
concomitance of factor-V Leiden and prothrombin G20210A was
not demonstrated, which may result from the exclusion of women
at highest risk of venous thromboembolism, or from the small
numbers sampled in the study.
Keywords Antithrombin deficiency, concomitance, fetal loss,
protein-C deficiency, protein-S deficiency.
Please cite this paper as: Korteweg F, Folkeringa N, Brouwer J, Erwich J, Holm J, van der Meer J, Veeger N. Fetal loss in women with hereditary thrombophi-
lic defects and concomitance of other thrombophilic defects: a retrospective family study. BJOG 2012;119:422–430.
Introduction
Hereditary deficiencies of antithrombin (AT), protein C
(PC) and protein S (PS) are strong risk factors for venous
thromboembolism (VTE).1–3 Women with these deficiencies
are at higher risk of VTE during pregnancy and the puerpe-
rium, because of the acquired hypercoagulable state associ-
ated with this condition.4–6 It is likely that not only maternal
veins but also maternal–placental vessels are more prone to
the development of thrombosis, as has been demonstrated in
women with mild thrombophilic defects.7–10 Consequently,
women with strong thrombophilic defects, i.e. deficiencies of
AT, PC or PS, may be at higher risk of fetal loss, because of
placental insufficiency as a result of placental infarction.
Thus far, only a few family studies addressed fetal loss in
women with these rare deficiencies.11–14 Although the
reported risk of fetal loss was increased compared with con-
trols,11,12 this result was not consistent in meta-analyses.13,14
Recently, it was demonstrated that the concomitance of
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subjects with hereditary deficiencies of AT, PC or PS.
Moreover, concomitance was frequently observed in fami-
lies with these deficiencies.3,15–17 Similarly, concomitance
might also increase the risk of fetal loss.
We performed a retrospective family cohort study to
assess the absolute risk of fetal loss associated with heredi-
tary deficiencies of AT, PC and PS, and the contribution of
additional thrombophilic defects to this risk.
Methods
We studied women from a retrospective study of families
with hereditary deficiencies of AT, PC, type-I PS or type-III
PS.2,3,9 The probands of the study were consecutive patients
with documented VTE, in whom one of these deficiencies
was demonstrated. They were referred with clinically sus-
pected VTE to our thrombosis outpatient clinic over a per-
iod of 12 years. First-degree relatives older than 15 years of
age were identified. As the number of probands deficient in
AT was small, second-degree relatives from a deficient par-
ent were also identified. The study was approved by the
institutional review board of our hospital. Informed consent
was obtained from all participants. In the present study,
women were eligible if they had been pregnant at least once
resulting in live birth or fetal loss, excluding ectopic and
terminated pregnancies. Considering the high risk of VTE
in women with hereditary deficiencies and the probability
that they had received thromboprophylaxis during pregnan-
cies after prior VTE, we excluded pregnancies after a prior
episode of VTE from analysis, because thromboprophylaxis
might have influenced the outcome of these pregnancies. As
a consequence, women without a pregnancy before the first
VTE were excluded. Detailed information about episodes of
venous thromboembolism, and the course and outcome of
previous pregnancies, from 15 years of age up to enrolment
was collected using a standardised questionnaire and by
reviewing medical records. We defined early fetal loss as loss
up to 22 weeks of gestation and late fetal loss as loss after
22 completed weeks of gestation, according to the criteria of
the World Health Organization.18 Recurrent fetal loss was
defined as two or more losses. Blood samples for testing on
thrombophilic defects were taken after clinical data had
been collected. These tests included factor-V Leiden and the
prothrombin G20210A mutation, in addition to all afore-
mentioned deficiencies.
Laboratory studies
The following methods described were used in a previous
study.6 AT activity (Coatest; Chromogenix, Mo¨lndal, Swe-
den) and PC activity (Berichrom Protein C; Dade Behring,
Marburg, Germany) were measured by chromogenic sub-
strate assay, and the Enzyme Linked Immuno Sorbent
Assay (DAKO, Glostrup, Denmark) was used to measure
PC-antigen and total and free PS-antigen levels. Normal
ranges were determined in 393 healthy blood donors that
had no (family) history of venous or arterial thromboem-
bolism, and were neither pregnant nor had used oral con-
traceptives for at least 3 months. We defined AT deficiency
by levels below the lower limit of its normal range
(<74 IU/dl), and type-I and type-II PC deficiency by low-
ered levels of PC antigen (<63 IU/dl) and/or activity
(<64 IU/dl). We defined type-I PS deficiency by total
(<67 IU/dl) and free PS levels (<65 IU/dl) below the lower
limit of their normal ranges, and type-III deficiency by
lowered free PS levels and normal total PS levels. We con-
sidered deficiencies to be inherited if they were confirmed
at repeated measurements of samples demonstrated in at
least two family members and collected at a 3-month inter-
val, whereas acquired conditions were excluded. A defi-
ciency was considered to be acquired, and to have resulted
from oral contraception or pregnancy, unless it was con-
firmed at least 3 months after the discontinuation of oral
contraception and delivery, respectively. Factor-V Leiden
and the prothrombin G20210A mutation were demon-
strated by polymerase chain reactions.19,20
In the probands and relatives who experienced VTE,
blood samples were collected at least 3 months after the
VTE had occurred. If they were undergoing treatment with
a vitamin-K antagonist, samples were taken after the ther-
apy had been interrupted and nadroparin had been admin-
istered subcutaneously.
Statistical analysis
Continuous variables were expressed as median values and
ranges, and categorical data were expressed as counts and
percentages. Differences between groups for continuous
data were evaluated using the Student’s t-test or Mann–
Whitney U-test, depending on the normality of data, and
by using the Fisher’s exact test or chi-square test for cate-
gorical data. The absolute fetal loss risks were expressed as
percentages of pregnancies resulting in fetal loss prior to
enrolment, i.e. prior to their classification as deficient or
non-deficient (see also Table 2). In addition, the percentage
of women with at least one fetal loss was calculated (see
also Table 1). For the estimation of the relative risks (i.e.
odds ratios), probands and deficient relatives were com-
pared with all non-deficient relatives. The odds ratios were
adjusted for clustering of pregnancies in women using the
generalised equation estimation methodology: a logistic
regression analysis with individual women as clustering
variables was performed to estimate odds ratios, with confi-
dence limits based on the Wald statistic. The effect of con-
comitant thrombophilic defects was assessed for factor-V
Leiden and the prothrombin G20210A mutation, compar-
ing women that are deficient or non-deficient. A two-tailed
P < 0.05 was considered to indicate statistical significance.
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Statistical analyses were performed using sas 9.1 (SAS
Institute Inc., Cary, NC, USA).
Results
Overall, of 89 female probands and 541 female relatives,
175 women were excluded because of age <15 years, death,
geographic distance and refused consent. A total of 455
women were eligible, of whom 136 were never pregnant
and two had only ectopic or terminated pregnancies.
Another 28 women were excluded because they had their
first pregnancy after VTE. The remaining 289 women were
analysed, of which 162 were deficient and 127 were non-
deficient (Figure 1). Their clinical characteristics are sum-
marised in Table 1. Overall, the median age at first preg-
nancy in women who were deficient or non-deficient was
comparable. At least one fetal loss was observed in 33% of
women who were deficient, whereas in women who were
non-deficient the loss was 28% (P = 0.37). These were
comparable in probands and deficient relatives (P = 0.86).
Of women who were deficient (including probands), 35%
had VTE at a fertile age, compared with 6% of women
who were non-deficient (P < 0.001). This difference was
less pronounced in the cohort of PS type-III deficient fami-
lies (23 versus 10%; P = 0.10). The concomitance of fac-
tor-V Leiden and/or the prothrombin G20210A mutation
was demonstrated in 23% of women who were deficient,
and in 14% of women who were non-deficient (P = 0.12).
The distribution of fetal loss related to gestational age in
women that are deficient or non-deficient for the separate
cohorts of families deficient in AT, PC, type-I PS and type-
III PS showed that early fetal loss mainly occurred between
6 and 12 weeks of gestation, and that late fetal loss
occurred between 36 and 42 weeks of gestation.
Table 2 shows the absolute risks of fetal loss as the total
number of fetal losses out of the total number of pregnan-
cies. The total fetal loss rates were 23% in women deficient
in AT, 26% in women deficient in PC, 11% in women defi-
cient in type-I PS and 15% in women deficient in type-III
PS, compared with 11, 18, 12 and 13% in non-deficient
women, respectively. Adjusted for the clustering of preg-
nancies among the women, and compared with all non-
deficient women, odds ratios were 2.3 (95% CI 0.9–6.1) in
women deficient in AT, 2.1 (95% CI 0.9–4.7) in women
deficient in PC, 0.7 (95% CI 0.2–1.8) in women deficient
in type-1 PS and 1.1 (95% CI 0.6–2.0) in women deficient
in type-III PS, none of which reached statistical signifi-
cance. Early fetal loss rates showed no statistically signifi-
cant differences between women who are deficient and
women who are non-deficient. Late fetal loss rates were 13
and 6% in women deficient in AT and women deficient in
PC, respectively; odds ratios were 11.3 (95% CI 3.0–42.0)
and 4.7 (95% CI 1.3–17.4). In women deficient in type-I
and type-III PS, the late fetal loss rates were 1 and 2%,
respectively; odds ratios were 0.9 (95% CI 0.1–7.8) and 1.9
(95% CI 0.6–6.4), and did not reach statistical significance.
Of 289 women who were included in our analysis, 273
(94%) were tested on factor-V Leiden and the prothrombin
G20210A mutation. The concomitance of these mutations
was demonstrated in 52 women (19%): 6% were double
heterozygotes (see Table 3 for the separate and pooled
cohorts). These thrombophilic defects were observed more
frequently in both women who were deficient and women
who were non-deficient than is expected in the normal
Table 1. Clinical characteristics of 289 women with hereditary deficiencies of antithrombin, protein C or protein S, and their non-deficient
female relatives
Antithrombin Protein C Protein S type I Protein S type III
Def. Non-def. Def. Non-def. Def Non-def. Def. Non-def.
Women, n 19 19 31 32 29 28 83 48
Age at first pregnancy,
median (range)
27 (16–34) 25 (18–40) 23 (15–33) 25 (17–32) 25 (17–34) 26 (18–32) 24 (17–37) 25 (16–37)
1 pregnancy, n (%) 6 (31) 2 (10) 7 (23) 3 (9) 9 (31) 3 (11) 17 (20) 6 (12)
2 pregnancies, n (%) 6 (32) 6 (32) 9 (29) 12 (38) 8 (28) 11 (39) 15 (18) 16 (33)
3 pregnancies, n (%) 3 (16) 7 (37) 7 (23) 5 (16) 7 (24) 10 (36) 27 (33) 8 (17)
4 or more pregnancies, n (%) 4 (21) 4 (21) 8 (25) 12 (37) 5 (17) 4 (14) 24 (29) 18 (38)
At least 1 fetal loss, n (%) 9 (47) 6 (32) 14 (45) 9 (28) 6 (21) 8 (29) 25 (30) 13 (27)
Recurrent fetal loss, n (%) 1 (5) 1 (5) 4 (13) 6 (19) 2 (7) 1 (4) 9 (11) 3 (6)
VTE at fertile age, n (%) 9 (47) 0 13 (42) 1 (3) 15 (52) 1 (4) 19 (23) 5 (10)
Concomitance, n/n (%)* 3/16 (19) 3/15 (20) 6/29 (21) 5/29 (17) 8/27 (30) 1/27 (4) 18/83 (22) 8/47 (17)
*Concomitance of factor-V Leiden and/or prothrombin G20210A; n affected/n tested (%).
Korteweg et al.
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Table 2. Total, early and late fetal loss rates in 289 women with 860 pregnancies with hereditary deficiencies of antithrombin, protein C or
protein S, and their non-deficient relatives
Pregnancies
Analysed Total fetal loss Early fetal loss Late fetal loss
Antithrombin, n (%)
Deficient 47 11 (23) 5 (10) 6 (13)
Non-deficient 63 7 (11) 6 (9) 1 (2)
OR* (95% CI); P 2.3 (0.9–6.1); 0.10 0.8 (0.2–2.6); 0.70 11.3 (3.0–42.0); 0.0003
Protein C, n (%)
Deficient 88 23 (26) 18 (20) 5 (6)
Non-deficient 107 19 (18) 19 (18) 0 (0)
OR* (95% CI); P 2.1 (0.9–4.7); 0.07 1.6 (0.7–3.8); 0.25 4.7 (1.3–17.4); 0.02
Protein S type I, n (%)
Deficient 73 8 (11) 7 (10) 1 (1)
Non-deficient 73 9 (12) 7 (9) 2 (3)
OR* (95% CI); P 0.7 (0.2–1.8); 0.40 0.6 (0.2–1.8); 0.37 0.9 (0.1–7.8); 0.90
Protein S type III, n (%)
Deficient 261 39 (15) 33 (13) 6 (2)
Non-deficient 148 19 (13) 17 (12) 2 (1)
OR* (95% CI); P 1.1 (0.6–2.0); 0.78 1.1 (0.6–2.0); 0.83 1.9 (0.6–6.4); 0.30
All non-deficient 391 54 (14) 49 (13) 5 (1)
CI, confidence interval.
*Odds ratios (ORs) were adjusted for clustering of pregnancies in women, and compared with all non-deficient women using the generalised
equation estimation methodology. In this, a logistic regression analysis with individual women as clustering variable was performed to estimate
ORs with confidence limits based on the Wald statistic.
Deficiency 
(families, n)     
Female probands
Female relatives
Total women  
Exclusion  
Eligible women  
Never pregnant          
Women with only  
pregnancies after VTE 
Evaluable women  
Deficient  
Non-deficient  
*Two women only had ectopic or terminated pregnancies. 
69
33 
Antithrombin   
(12) 
 Protein C   
(40) 
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141 630
109




27 37 27 47* 138* 




4 9 9 6 28
89
Figure 1. Recruitment of women from families with hereditary deficiencies of antithrombin, protein C or protein S.
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population (i.e. factor-V Leiden, 5%, and the prothrombin
G20210A mutation, 3%).
The risks of total, early and late fetal loss in women with
deficiencies of either AT or PC, and the reference group,
with or without the concomitance of thrombophilic defects,
are presented in Table 4. In women deficient in AT or PC,
the total fetal loss rates were 44% (four of nine) in women
with a concomitance of thrombophilic defects, versus 44%
(16 of 36) in women without a concomitance of thrombo-
philic defects (Table 4). In women from the reference group,
consisting of women who were not deficient in AT or PC,
but who were deficient in type-I or type-III PS, and non-
deficient women, the fetal loss rates with and without a con-
comitance of thrombophilic defects were 23 and 29%,
respectively. The observed differences in risk of early and late
fetal loss within subgroups (women deficient in AT or PC
and women from the reference group) with and without the
concomitance of thrombophilic defects were not statistically
significant. Again, the numbers were small.
Discussion
This study showed a high absolute risk of fetal loss in
women with hereditary deficiencies of AT or PC. In women
with hereditary deficiencies of type-I and type-III PS, the
risk was comparable with non-deficient women. Odds
ratios of total fetal loss were not statistically significant in
deficient women, although there was some suggestion that
late as opposed to early fetal loss rates were different. The
concomitance of factor-V Leiden and/or the prothrombin
G20210A mutation apparently did not influence the risk of
fetal loss.
The absolute risk of total fetal loss in our study was 23%
in women deficient in AT and 26% in women deficient in















Deficient 16/19 1 (6.3) 2 (12.5) 3 (18.8)
Non-deficient 15/19 0 (0) 3 (20.0) 3 (20.0)
Protein C
Deficient 29/31 4 (13.8) 2 (6.9) 6 (20.7)
Non-deficient 29/32 5 (17.4) 0 (0) 5 (17.4)
Protein S, type I
Deficient 27/29 7 (25.9) 1 (3.7) 8 (29.6)
Non-deficient 27/28 1 (3.6) 1 (3.7) 1 (3.7)
Protein S, type III
Deficient 83/83 11 (13.3) 9 (10.8) 18 (21.7)
Non-deficient 47/48 6 (12.8) 2 (4.3) 8 (17.0)
Antithrombin or protein C
Deficient 45/50 5 (11.1) 4 (8.5) 9 (20.0)
Reference group* 228/239 30 (13.1) 16 (7.0) 43 (18.9)
*Reference group consisted of: women not deficient in antithrombin and protein C, women deficient in type-I and type-III protein S and non-defi-
cient women.
Table 4. Risks of total, early and late fetal loss in women with
hereditary deficiencies of antithrombin or protein C, and the









Antithrombin or protein C deficient
Concomitance 4/9 (44.4) 3/9 (33.3) 1/9 (11.1)
No concomitance 16/36 (44.4) 10/36 (27.8) 8/36 (22.2)
Reference group*
Concomitance 10/43 (23.3) 9/43 (20.9) 3/43 (7.0)
No concomitance 53/185 (28.7)** 47/185 (25.4) 8/185 (4.3)***
*The reference group consisted of women who were not deficient
in antithrombin and protein C, women who were deficient in type-I
and type-III protein S and non-deficient women.
**P = 0.08.
***P = 0.001, compared with women deficient in antithrombin or
protein C, without the concomitance of thrombophilic defects.
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PC: 2.3- and 2.1-fold higher than in non-deficient women.
Previous studies showed odds ratios of total fetal loss rang-
ing from 1.5 to 2.5 in women deficient in AT, and ranging
from 1.4 to 2.5 in women deficient in PC, compared with
controls.11–13 Although the odds ratios in our study were
in agreement with previous studies, the absolute risks in
relatives not deficient in AT and PC (11 and 18%, respec-
tively) were higher than in the risks in the controls
reported by Preston et al.11 In that study, the controls were
partners of male participants in the European Prospective
Cohort on Thrombophilia (EPCOT) or were acquaintances
of women in the study. As we compared deficient women
with their non-deficient relatives, the concomitance of
other thrombophilic defects in these families might explain
the higher risk of fetal loss in non-deficient as well as defi-
cient women. The results suggest that the higher risk of
fetal loss in women deficient in AT and PC mainly reflects
an 11.3- and 4.7-fold increased rate of late fetal loss,
although further research is needed as numbers are small.
Early fetal loss was comparable with non-deficient relatives.
Preston et al.11 found an odds ratio for early fetal loss of
1.7 (95% CI 1.0–2.8) in women deficient in AT and 1.4
(95% CI 0.9–2.2) in women deficient in PC, whereas this
was 5.2 (95% CI 1.5–18.1) for late fetal loss in women defi-
cient in AT and 2.3 (95% CI 0.6–8.3) in women deficient
in PC.
We observed the lowest excess risk for total fetal loss in
women deficient in type-I and type-III PS. The total fetal
loss risks, as well as early and late fetal loss risks, were
comparable with non-deficient relatives for both types of
PS deficiency. Preston et al.11 found a comparable odds
ratio of 1.3 (95% CI 0.8–2.1) for total fetal loss in women
deficient in PS, whereas it was 3.3 (95% CI 1.0–11.3) for
late fetal loss. In a meta-analysis the risk for total fetal loss
was even 7.4-fold higher (95% CI 1.3–42.8).13 In contrast
with previous studies, we separately assessed the risk of
fetal loss in women with type-I and type-III PS deficiency,
because we previously had demonstrated that type-III PS
deficiency was not a risk factor for VTE.2 The assumption
that it might also not be associated with an increased risk
for fetal loss was supported by our data. It is remarkable,
however, that type-I PS deficiency did not influence the
risk of fetal loss, considering that it is comparable with AT
deficiency and PC deficiency as a risk factor for VTE.5,6
In our study, the concomitance of factor-V Leiden and
the prothrombin G20210A mutation apparently did not
influence the risk of fetal loss in either deficient or non-
deficient women. In fact we observed a comparable, rather
than higher, risk of fetal loss in women deficient in AT and
PC with the concomitance of factor-V Leiden and the pro-
thrombin G20210A mutation, although the numbers were
small. The exclusion of pregnancies after prior VTE could
be an explanation for this finding. The concomitance of
other thrombophilic defects results in a higher risk and ear-
lier onset of VTE in women with deficiencies of AT, PC or
PS.3 One would expect that the concomitance of other
thrombophilic defects also increased the risk of fetal loss.11
By excluding pregnancies after prior VTE from the analysis,
we probably excluded women at the highest risk of VTE,
i.e. deficient women with concomitance, and consequently
women with potentially the highest risk of fetal loss.
Indeed, the concomitance of factor-V Leiden and the pro-
thrombin G20210A mutation was more frequently observed
in excluded women than in analysed women (data not
shown), whereas the former showed a higher total fetal loss
rate. Our assumption that thromboprophylaxis during
pregnancy in deficient women reduced the estimated risk
of fetal loss was further supported by the previously
reported results of a prospective observational study on the
same family cohort.21 That study showed a fetal loss rate of
0% in deficient women, who received thromboprophylaxis
during pregnancy, compared with 45% in deficient women
who did not (P = 0.001).
A comparison of our results with previous reports on
fetal loss related to thrombophilic deficiencies and other
thrombophilic defects is hampered by differences in meth-
odology. The majority of previous studies addressed the
incidence of thrombophilic defects in women with adverse
pregnancy outcomes.7,9,13,14,22–24 We assessed fetal loss rates
in families with hereditary deficiencies, which were identi-
fied by testing consecutive patients with VTE. Furthermore,
gestational ages ranged widely in previous studies, and
some studies did not differentiate between early and late
fetal loss. However, placental function depends on gesta-
tional age,25,26 and the mechanisms of early and late fetal
loss differ. Although placental thrombosis is a plausible
explanation for (late) fetal loss in deficient women, defi-
ciencies of AT, PC and PS may also contribute to another
pathophysiological mechanism. Experiments in mice pro-
vided evidence that fibrin degradation products induce
apoptosis of throphoblasts, resulting in fetal loss.27 As it is
likely that deficiencies of AT, PC and PS are associated
with the increased generation of thrombin and, conse-
quently, fibrin and fibrin degradation products, we specu-
late that deficient women will be more prone to fetal loss
than non-deficient women. In deficient women, early fetal
loss may be a result of apoptosis of throphoblasts, whereas
late fetal loss may be a result of placental thrombosis. In
accordance with this hypothesis, anticoagulant treatment
during pregnancy might have a beneficial effect on both
early and late fetal loss in deficient women, as suggested by
the results of a prospective study mentioned previously.21
This study has some limitations. The numbers of suba-
nalyses were small, leading to wide imprecise confidence
intervals. The absolute risk of fetal loss in deficient
women may have been underestimated by excluding preg-
Fetal loss and multiple thrombophilic defects
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nancies after prior VTE, and consequently women at
higher risk of fetal loss. It is also important to keep in
mind that the group of deficient women we studied are
from highly thrombophilic families, and these results can
therefore not be applied to women proven to be throm-
bophilia deficient without positive family members. In
addition, different genetic forms of hereditary deficiencies
of AT, PC or PS, regarding mutations or polymorphisms,
may carry a higher risk for pregnancy complications; this
should be addressed in future studies. Although a system-
atic search for the causes of early and late fetal loss (e.g.
chromosomal abnormalities and infections) was not per-
formed because of the retrospective design of our study,
it is not likely that these would strongly differ among
deficient and non-deficient women. In our analysis we did
control for clustering of pregnancies within women.
Because of the small numbers, additional adjustment for
confounding was not feasible. We can only speculate
about the impact of other important risk factors of fetal
loss among deficient and non-deficient women. We feel
that this lack of further control, however, did not signifi-
cantly influence our findings. Recall bias regarding fetal
loss may have been introduced by its retrospective design,
but its influence remained limited as clinical data was col-
lected prior to the classification of women as deficient or
non-deficient. In addition, patients were not selected
because of their compromised obstetrical history. Referral
bias cannot be excluded by the setting of a university hos-
pital. Selection bias is not very likely, as consecutive
patients with VTE were tested to identify probands and
their relatives, rather than women with fetal loss.
Conclusion
There was some suggestion that hereditary deficiencies of
AT and PC were associated with a higher absolute risk of
late fetal loss, in contrast with PS deficiency. An additional
effect of the concomitance of other thrombophilic defects,
although plausible, was not demonstrated, maybe as a
result of excluding women at the highest risk of VTE. Fur-
ther research is needed.
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Journal club
A retrospective family study investigating the risk of fetal loss in women
with hereditary deficiencies of antithrombin and protein C, compared with
protein S, and contribution of the concomitance of other thrombophilic
defects
Background
• Describe recommendations for thrombophilia testing in women with late fetal loss,1 with reference to whether such
testing should be routine or selective. Debate whether the recommendations should be modified in light of the findings
from this study.
• How common are thrombophilias, e.g. factor-V mutation?
Methods
• Critically appraise the method of selecting patients and controls for this study.
• Debate the authors’ decision to exclude pregnancies with prior venous thromboembolism, and the impact of this
decision on the results.
Results and implications
• Absolute risks of total fetal loss were high and odds ratios of late fetal loss were significant for women with
anti-thrombin and protein C deficiency, compared with their non-deficient relatives: discuss.
• Consider the possible influence of body mass index on the results.
• Can results from this study be used to counsel women with specific thrombophilia deficiencies pre-pregnancy
and antenatally? (Data S1)
Fetal loss and multiple thrombophilic defects
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